WHO-CHOICE Interventions
Cardiovascular Disease
-
More Information
Details on methods: Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N, Rodgers A, Lawes CMM, Evans DB (March 2003)Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk The Lancet, 361: 717-725 - Cost-Effectiveness Results
| CODE | DESCRIPTION |
| CVD-2 | Salt reduction in food (voluntary): Voluntary co-operation of food manufacturers with government to decrease salt in processed food plus appropriate labelling |
| CVD-3 | Salt reduction in food (enforced): Legislation to decrease salt content of processed foods plus appropriate labelling and enforcement |
| CVD-4 | Health education through mass media to reduce cholesterol |
| CVD-5 | Hypertension-lowering drug treatment (DRG) and education (ED) on lifestyle modification including dietary advice, delivered by physicians to individuals with systolic blood pressure (SBP) >160 mmHg. |
| CVD-6 | As above with systolic BP> 140 mm Hg |
| CVD-7 | Cholesterol-lowering drug treatment (statins) and education (ED) on lifestyle modification including dietary advice, delivered by physicians to individuals whose serum cholesterol concentration (CHOL) exceeds 220 mg/dl (5.7 mmol/l) |
| CVD-8 | Statins and ED with CHOL >240 mg/dl (>6.2 mmol/l) |
| CVD-9 | Treatment with triple therapy of hypertension lowering drug (beta-blocker), statins and aspirin for individuals with absolute risk of cardiovascular event of 5% in 10 years |
| CVD-10 | Treatment with triple therapy of hypertension lowering drug, statins and aspirin for individuals with absolute risk of cardiovascular event of 15% in 10 years |
| CVD-11 | Treatment with triple therapy of hypertension lowering drug, statins and aspirin for individuals with absolute risk of cardiovascular event of 25% in 10 years |
| CVD-12 | Treatment with triple therapy of hypertension lowering drug, statins and aspirin for individuals with absolute risk of cardiovascular event of 35% in 10 years |
| CVD-13 | Combination (CVD2 + CVD3) |
| CVD-14 | Combination (CVD6 + CVD7) |
| CVD-15 | Combination (CVD2 + CVD3 + CVD9) |
| CVD-16 | Combination (CVD2 + CVD3 + CVD10) |
| CVD-17 | Combination (CVD2 + CVD3 + CVD11) |
| CVD-18 | Combination (CVD2 + CVD3 + CVD12) |